Wet-AMD Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Qilu

DelveInsight’s “Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Wet Age-Related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Wet Age-Related Macular Degeneration Market Forecast

Some of the key facts of the Wet Age-Related Macular Degeneration Market Report: 

• The Wet Age-Related Macular Degeneration market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total prevalent cases of Age-Related Macular Degeneration in the 7MM was found to be approximately 51,743,361 cases in 2021. These cases are expected to increase by 2032 with respect to many factors risk factor like age, better treatment and awareness
• Among the 7MM, the United States had the highest prevalent cases of Age-Related Macular Degeneration with approximately 17,282,569 cases in 2021
• The total diagnosed prevalent cases of Age-Related Macular Degeneration in the 7MM was found to be approximately 38,807,521 cases in 2021. These cases are expected to increase by 2032
• Key Wet Age-Related Macular Degeneration Companies: Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Qilu Pharmaceutical Co., Ltd., Alkahest, Inc., EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Novartis, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., Sam Chun Dang Pharm. Co. Ltd., Ophthotech Corporation, IVERIC bio, Inc., OPKO Health, Inc., Boehringer Ingelheim, and others
• Key Wet Age-Related Macular Degeneration Therapies: OPT-302, RGX-314, AKST4290, GB-102, Aflibercept, ALK4290, Eyp-1901, RC28-E, ranibizumab, SCT510A, MW02, SCD411, Zimura, Lucentis, Bevasiranib, BI 144807, and others
• The Age-Related Macular Degeneration epidemiology based on type-specific cases analyzed that prevalence of Dry Age-Related Macular Degeneration is higher than Wet Age-Related Macular Degeneration
• The Wet Age-Related Macular Degeneration market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Wet Age-Related Macular Degeneration pipeline products will significantly revolutionize the Wet Age-Related Macular Degeneration market dynamics.

Wet Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, with a profound effect on the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the health care systems with the expensive current standard of care.

Get a Free sample for the Wet Age-Related Macular Degeneration Market Report –

https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market

Wet Age-Related Macular Degeneration Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Wet Age-Related Macular Degeneration Epidemiology Segmentation:

The Wet Age-Related Macular Degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Wet Age-Related Macular Degeneration
• Prevalent Cases of Wet Age-Related Macular Degeneration by severity
• Gender-specific Prevalence of Wet Age-Related Macular Degeneration
• Diagnosed Cases of Episodic and Chronic Wet Age-Related Macular Degeneration

Download the report to understand which factors are driving Wet Age-Related Macular Degeneration epidemiology trends @ Wet Age-Related Macular Degeneration Epidemiology Forecast

Wet Age-Related Macular Degeneration Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Wet Age-Related Macular Degeneration market or expected to get launched during the study period. The analysis covers Wet Age-Related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Wet Age-Related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Wet Age-Related Macular Degeneration Therapies and Key Companies

• OPT-302: Opthea Limited
• RGX-314: Regenxbio
• AKST4290: Alkahest
• GB-102: Graybug Vision

Discover more about therapies set to grab major Wet Age-Related Macular Degeneration market share @ Wet Age-Related Macular Degeneration Treatment Market

Wet Age-Related Macular Degeneration Market Drivers

• Increasing prevalence of wet AMD
• Development in the field of gene therapy
• Robust pipeline
• Novel oral formulations for the treatment of wet AMD

Wet Age-Related Macular Degeneration Market Barriers

• High cost of treatment
• Competitive treatment landscape
• Emerging biosimilars
• Low compliance

Scope of the Wet Age-Related Macular Degeneration Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Wet Age-Related Macular Degeneration Companies: Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Qilu Pharmaceutical Co., Ltd., Alkahest, Inc., EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Novartis, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., Sam Chun Dang Pharm. Co. Ltd., Ophthotech Corporation, IVERIC bio, Inc., OPKO Health, Inc., Boehringer Ingelheim, and others
• Key Wet Age-Related Macular Degeneration Therapies: OPT-302, RGX-314, AKST4290, GB-102, Aflibercept, ALK4290, Eyp-1901, RC28-E, ranibizumab, SCT510A, MW02, SCD411, Zimura, Lucentis, Bevasiranib, BI 144807, and others
• Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Wet Age-Related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Wet Age-Related Macular Degeneration Market Access and Reimbursement 

To know more about Wet Age-Related Macular Degeneration companies working in the treatment market, visit @ Wet Age-Related Macular Degeneration Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Wet Age-Related Macular Degeneration Market Report Introduction

2. Executive Summary for Wet Age-Related Macular Degeneration

3. SWOT analysis of Wet Age-Related Macular Degeneration

4. Wet Age-Related Macular Degeneration Patient Share (%) Overview at a Glance

5. Wet Age-Related Macular Degeneration Market Overview at a Glance

6. Wet Age-Related Macular Degeneration Disease Background and Overview

7. Wet Age-Related Macular Degeneration Epidemiology and Patient Population

8. Country-Specific Patient Population of Wet Age-Related Macular Degeneration 

9. Wet Age-Related Macular Degeneration Current Treatment and Medical Practices

10. Wet Age-Related Macular Degeneration Unmet Needs

11. Wet Age-Related Macular Degeneration Emerging Therapies

12. Wet Age-Related Macular Degeneration Market Outlook

13. Country-Wise Wet Age-Related Macular Degeneration Market Analysis (2019–2032)

14. Wet Age-Related Macular Degeneration Market Access and Reimbursement of Therapies

15. Wet Age-Related Macular Degeneration Market Drivers

16. Wet Age-Related Macular Degeneration Market Barriers

17.  Wet Age-Related Macular Degeneration Appendix

18. Wet Age-Related Macular Degeneration Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services